Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis
NCT ID: NCT06452173
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
300 participants
OBSERVATIONAL
2024-04-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study proposes using deep learning technology to integrate multidimensional data from plaque imaging, fluid dynamics, circulating metabolomics, and proteomics to construct an accurate prediction model for cerebrovascular events in patients with carotid artery stenosis. Additionally, it aims to explore markers of plaque instability characteristics based on plaque pathology. The study is expected to provide a basis for identifying high-risk patients with carotid artery stenosis, thereby laying the foundation for reducing stroke risk and improving long-term patient outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology.
NCT06978348
Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis
NCT02315924
Comprehensive Assessment of Atherosclerotic Ischemic Stroke Risk and Development of a Prediction Model
NCT06315153
Prediction Model for Chronic Intracranial Arterial Occlusion With Radiomic Features
NCT06066593
Physiological Magnetic Resonance Imaging (MRI) to Improve Carotid Endarterectomy Outcomes
NCT01272843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
high risk
Patients with cerebrovascular events within six months, including i. cerebral infarction in the middle cerebral artery territory on the side of carotid stenosis; ii. transient ischemic attack symptoms (including motor and sensory) in the hemisphere on the side of stenosis; and iii. transient amaurosis on the side of stenosis. This indicates an unstable condition and such patients are defined as high-risk carotid stenosis patients.
Plasma
Plasma levels of metabolites and some proteins will be further determined
carotid high-resolution magnetic resonance imaging
Define plaque composition and morphological characteristics
low risk
Patients without cerebrovascular events within six months are defined as low-risk carotid stenosis patients.
Plasma
Plasma levels of metabolites and some proteins will be further determined
carotid high-resolution magnetic resonance imaging
Define plaque composition and morphological characteristics
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma
Plasma levels of metabolites and some proteins will be further determined
carotid high-resolution magnetic resonance imaging
Define plaque composition and morphological characteristics
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those who signed informed consent and volunteered to participate in this study.
Exclusion Criteria
* Patients with combined cardiogenic embolism, vasculitis, entrapment aneurysm and other related cerebral infarction;
* Combination of tumors, rheumatic immune system diseases, hematologic diseases and other diseases that change blood metabolism and proteomic characteristics;
* There are contraindications to magnetic resonance scanning and allergy to gadolinium contrast agent;
* Inability to cooperate in completing the relevant examinations.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Neurosurgical Institute
OTHER
Beijing Tiantan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Neurosurgical Institution
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-2-1072
Identifier Type: OTHER
Identifier Source: secondary_id
KY2024-070-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.